Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial

Nguyen, Trong ToanTrong ToanNguyenChiu, Cheng-HsunCheng-HsunChiuLin, Chien-YuChien-YuLinChiu, Nan-ChangNan-ChangChiuChen, Po-YenPo-YenChenLe, Thi Tuong VyThi Tuong VyLeLe, Dang NganDang NganLeDuong, An HanAn HanDuongNguyen, Van LuanVan LuanNguyenHuynh, Thi NguyetThi NguyetHuynhTruong, Huu KhanhHuu KhanhTruongPhan, Trong LanTrong LanPhanNguyen, Thi Thanh ThaoThi Thanh ThaoNguyenShih, Shin-RuShin-RuShihHuang, Chung-GueiChung-GueiHuangWeng, Yi-JenYi-JenWengHsieh, Erh-FangErh-FangHsiehChang, StanleyStanleyChangChen, CharlesCharlesChenTai, I-ChenI-ChenTaiLI-MIN HUANG2023-01-182023-01-182022-04-300140-6736https://scholars.lib.ntu.edu.tw/handle/123456789/627430Children are susceptible to severe or fatal enterovirus 71 (EV71) infections. We aimed to evaluate the efficacy, safety, and immunogenicity of EV71vac, an aluminium phosphate-adjuvanted inactivated EV71 vaccine in children aged 2-71 months.enMOUTH-DISEASE; FOOT; HAND; PATHOGENESIS; CHINA[SDGs]SDG3[SDGs]SDG9Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trialjournal article10.1016/S0140-6736(22)00313-0354274812-s2.0-85129197035WOS:000798562500020https://api.elsevier.com/content/abstract/scopus_id/85129197035